Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Conclusion.This is a novel decision that will become more common as the prevalence of patients with well‐controlled CML continues to increase. These results highlight the need for patient education and decision support so that patients and providers can make shared decisions that are informed and values based.Implications for Practice.The standard treatment for chronic phase chronic myeloid leukemia (CML) is lifelong oral tyrosine kinase inhibitor (TKI) therapy. Clinical trials have shown that some patients with a sustained deep molecular response to TKI therapy can safely stop therapy and remain in a treatment‐free remission. TKI discontinuation is now being offered to patients outside of clinical trials. This study explored factors that patients who are eligible to try TKI discontinuation considered when making this decision. Factors relevant to the decision included risk of relapse, side effects, financial considerations, polypharmacy, and willingness to change something that was working. This is a novel decision that will become more common as the prevalence of patients with well‐controlled CML continues to increase. These results highlight the need for decision support and outline the factors that should be included so that patients and providers can make shared decisions that are informed and values based.

Source: The Oncologist - September 10, 2019 Category: Cancer & Oncology Authors: Kathryn E. Flynn, Judith M. Myers, Anita D'Souza, Charles A. Schiffer, James E. Thompson, Ehab Atallah Tags: Leukemias, Symptom Management and Supportive Care, Hematologic Malignancies, Health Outcomes and Economics of Cancer Care Source Type: research